Monitor this situation.

Unsubscribe anytime.

[SITUATION] · [QUIET] · [HEALTH]

2 clusters · 5 sources · 16 days · First seen 28 days ago · Last updated 13 days ago

GLP-1 weight-loss drug market regulation in Africa

Overview

The market for GLP-1 weight-loss medications is expanding significantly across Africa, with South Africa serving as a primary hub. While the market has reached substantial valuations, the surge in demand has led to increased regulatory scrutiny and the emergence of illicit trade.

Regulators, including the South African Health Products Regulatory Authority (SAHPRA) and the South African Pharmacy Council (SAPC), have taken action against unauthorized compounding practices to prevent the manufacturing of counterfeit medicines. Concerns have been raised regarding a growing black market where unregistered drugs, such as the experimental retatrutide, are sold through informal channels like social media and gym instructors.

In response to high costs and regulatory crackdowns, new service models have emerged. The health management programme Obiflex introduced a ‘buy now, pay later’ option, providing virtual consultations and interest-free installments to help patients access legitimate medication while avoiding unregulated alternatives.

Entities

South African Health Products Regulatory Authority · South African Pharmacy Council · Novo Nordisk · Grovest · Shaun Barns

Claims

What the coverage asserts, and how many sources carry each claim.

[○ 1 SOURCE] Aspen reported that the local GLP-1 market in South Africa nearly doubled to approximately 170 million USD for the fiscal year ending June 2026.
[○ 1 SOURCE] Novo Nordisk launched Ozempic and Wegovy in Kenya in September 2026.
[○ 1 SOURCE] The South African Pharmacy Council and SAHPRA are developing updated standards and guidelines for compounding medicines.
[○ 1 SOURCE] The South African Pharmacy Council expressed concern regarding pharmacies acting as small-scale manufacturers through large-scale compounding.
[○ 1 SOURCE] The experimental obesity drug retatrutide is being sold openly in South Africa despite not being approved by any regulator.
[○ 1 SOURCE] The Pharmaceutical Task Group has called for law enforcement action against the sale of unregistered medicines.

Timeline

13 days ago

[HEALTH] 3 sources
South Africa regulates weight-loss drug compounding amid rising black market
South Africa is tightening regulations on compounded weight-loss drugs as the GLP-1 market grows and illegal, unregistered medicines are sold through informal channels and social media.
28 days ago

[HEALTH] 2 sources
Obiflex introduces installment payments for GLP-1 weight-loss drugs in South Africa
Obiflex has launched a ‘buy now, pay later’ service in South Africa to help patients afford GLP-1 weight-loss medications, aiming to provide a legitimate alternative to unregulated illicit drugs.

Sources

afrikactus.com · algoafm.co.za · citizen.co.za · srnnews.com · thesouthafrican.com